Edition:
United States

Agenus Inc (AGEN.O)

AGEN.O on Consolidated Issue listed on NASDAQ Capital Market

7.18USD
30 Sep 2016
Change (% chg)

$0.31 (+4.51%)
Prev Close
$6.87
Open
$7.02
Day's High
$7.20
Day's Low
$7.00
Volume
1,409,066
Avg. Vol
1,090,232
52-wk High
$7.31
52-wk Low
$2.61

AGEN.O

Chart for AGEN.O

About

Agenus Inc. (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to... (more)

Overall

Beta: 2.04
Market Cap(Mil.): $597.69
Shares Outstanding(Mil.): 87.00
Dividend: --
Yield (%): --

Financials

  AGEN.O Industry Sector
P/E (TTM): -- 43.83 36.83
EPS (TTM): -1.03 -- --
ROI: -55.83 -0.29 13.93
ROE: -171.10 -2.99 14.84

BRIEF-Agenus Q2 loss per share $0.33

* Agenus reports second quarter 2016 financial results and operational progress

Jul 28 2016

BRIEF-Agenus' chief financial officer, C.Evan Ballantyne to resign

* On july 14, 2016, C. Evan Ballantyne, chief financial officer informed agenus of his intention to resign - sec filing

Jul 19 2016

BRIEF-Agenus Inc starts phase 1/2 clinical trial of anti-GITR agonist antibody

* Expect to initiate additional clinical studies with antibodies and immuno-oncology leads from comprehensive pipeline in next twelve months

Jun 22 2016

BRIEF-Agenus announces lead product candidate selection in Merck collaboration

* Agenus announces lead product candidate selection in its collaboration with Merck

Jun 09 2016

BRIEF-Agenus reports Q1 loss per share $0.37

* Agenus reports first quarter 2016 financial results and operational progress

Apr 28 2016

BRIEF-Agenus commences phase 1 clinical trial of antibody to treat solid tumors

* Agenus Commences Phase 1 Clinical Trial Of Its CTLA 4 checkpoint antibody to treat solid tumors

Apr 27 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : Jefferson Research
$20.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.